With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe.
Tomorrow’s cures for retinopathies will likely include advanced gene and cell therapies delivered by precision surgery.
We should be thrilled with the success of the approved CD-19 CAR-T therapies. But the field is still young, and we are only scratching the surface.
Sitting Down With... Bruce Levine, Professor in Cancer Gene Therapy, Perelman School of Medicine, University of Pennsylvania.
We sat down with David Eidelberg shortly after the publication of his group’s most recent paper in Science Translational Medicine.
Regulators step in to stop stem cell clinics from marketing unproven therapies.
The promise of genome editing is tempered for genetically heterogeneous diseases – introducing a new approach for rhodopsin-dependent retinitis pigmentosa.
Is gene therapy the answer to an untreatable form of macular degeneration?
Stem cells hold great promise, but is it the cells we really need?
What are the realities of translating exciting cell and gene therapy research into something more tangible?
Send me the latest from The Translational Scientist.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.